

Press Release 05/2011

Curetis AG successfully increases Series A financing round to EUR 24.5 million

CD-Venture joins strong syndicate of existing VC investors

Holzgerlingen, May 17, 2011 -- Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series A financing, bringing the total size of the round to € 24.5 million. CD-Venture joined the funding as a new investor, while all of Curetis' existing VC investors participated in the round. Several private investors also continued to co-invest.

Following the appointment of Oliver Schacht, PhD, as the new CEO of Curetis last month, this financing transaction is the first step towards funding next year's commercial launch and roll-out of the Unyvero product platform together with the first CE marked IVD test cartridge for pneumonia and antibiotic resistances in Europe. The additional funds will allow Curetis to pursue a more aggressive strategy towards initiating a US clinical trial in H2-2011 with a goal of filing for FDA approval in 2012. This Series A financing positions Curetis as a solidly funded molecular diagnostics company with near-term commercial-stage products and its unique platform solution addressing a clear unmet medical need in the rapid diagnosis of infectious diseases and antibiotic resistance.

"This is an ideal point in time to support Curetis," said Christoph Boehringer, Managing Director and Partner of CD-Venture, Curetis' new investor. "The upcoming launch of the Unyvero platform and the start of the first pivotal trial of a Curetis IVD product are key milestones that mark the company's entry into the next phase of corporate development and commercialization activities. Besides, the management team has established a track record for delivering on ambitious goals and brings together all the complementary skill sets to make Curetis a successful molecular diagnostics player in the space of severe infectious disease detection and antibiotic resistance testing."

"We are very pleased that CD-Venture joined our strong syndicate of VC investors," said Oliver Schacht, CEO of Curetis AG. "We are also happy to see that all of our current institutional investors such as aeris Capital, LSP Life Sciences Partners, BioMedInvest and KfW as well as many of our private shareholders have continued to subscribe to new shares. Their commitment is based on the excellent progress in R&D and clinical development and all the milestones the team has met over the past couple of months." Schacht added: "From this solid financial position we will also evaluate further opportunities to accelerate our commercialization and broaden our pipeline. In doing so we are also considering adding another investor and raising additional capital as we continue executing on our plans."



Curetis' CEO Oliver Schacht will present an update on the company at the upcoming BioEquity 2011 in Paris. The presentation is scheduled for May 23rd, 2011, at 5:00 pm CET, Room *Pont de Sully*.

About Curetis

Founded in 2007, Curetis AG is a molecular diagnostics company focusing on the development and commercialization of in-vitro products for the reliable, fast and cost-effective diagnosis of severe infectious diseases. The Curetis Unyvero platform solution will enable rapid multi-parameter pathogen and antibiotic resistance detection within only a few hours - a process that can take up to several days with currently available technologies.

To date, Curetis has raised total funds of over € 27 million (~ USD 40 million). The company is based in Holzgerlingen near Stuttgart, Germany.

About the Unyvero Platform

The Unyvero platform is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.

The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.

Thereby, clinical information is available within a few hours to support an informed therapy decision as early as possible.

The first Unyvero cartridge, Unyvero P50, focuses on pathogen as well as antibiotic resistance testing for pneumonia and simultaneously analyses more than 40 DNA targets. Cartridges for further applications, e.g. for surgical site infections, blood stream infections and tuberculosis, are in preparation.

Contact:

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany

Tel. +49 (0) 7031 49195-12

pr@curetis.com
www.curetis.com

Media Inquiries:

akampion
Dr. Ludger Wess, Managing Partner

Tel. +49 40 88165964
Cell: +49 160 966 529 58

ludger@akampion.com